These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38348690)

  • 1. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
    Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
    Future Oncol; 2024; 20(16):1057-1067. PubMed ID: 38348690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
    Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
    Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRG1 fusions: Biology to therapy.
    Liu SV
    Lung Cancer; 2021 Aug; 158():25-28. PubMed ID: 34098222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
    Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
    Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
    Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRG1 Fusions in NSCLC: Being eNRGy Conscious.
    Gupta B; Gosa Barrett L; Liu SV
    Lung Cancer (Auckl); 2024; 15():143-148. PubMed ID: 39376790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
    Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
    Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
    Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
    Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
    Gan HK; Millward M; Jalving M; Garrido-Laguna I; Lickliter JD; Schellens JHM; Lolkema MP; Van Herpen CLM; Hug B; Tang L; O'Connor-Semmes R; Gagnon R; Ellis C; Ganji G; Matheny C; Drilon A
    Oncologist; 2021 Oct; 26(10):e1844-e1853. PubMed ID: 34132450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
    Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
    J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
    Severson E; Achyut BR; Nesline M; Pabla S; Previs RA; Kannan G; Chenn A; Zhang S; Klein R; Conroy J; Sausen M; Sathyan P; Saini KS; Ghosh A; Jensen TJ; Reddy P; Ramkissoon SH
    J Mol Diagn; 2023 Jul; 25(7):454-466. PubMed ID: 37164276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.
    Kim HS; Han JY; Shin DH; Lim KY; Lee GK; Kim JY; Jacob W; Ceppi M; Weisser M; James I
    Lung Cancer; 2018 Oct; 124():71-75. PubMed ID: 30268483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to ERBB3-Directed Targeted Therapy in
    Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
    Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
    [No Abstract]   [Full Text] [Related]  

  • 18. Detection of NRG1 Gene Fusions in Solid Tumors.
    Jonna S; Feldman RA; Swensen J; Gatalica Z; Korn WM; Borghaei H; Ma PC; Nieva JJ; Spira AI; Vanderwalde AM; Wozniak AJ; Kim ES; Liu SV
    Clin Cancer Res; 2019 Aug; 25(16):4966-4972. PubMed ID: 30988082
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
    Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.
    Zhang C; Mei W; Zeng C
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188707. PubMed ID: 35247506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.